Trial · NCT04669366
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With at Least 1 Filled Sunitinib Prescription | Sunitinib 4:2 Schedule | 704 | Participants | ||
| Number of Participants With at Least 1 Filled Sunitinib Prescription | Sunitinib 2:1 Schedule | 320 | Participants | ||
| Number of Participants With at Least 1 Filled Sunitinib Prescription | Sunitinib: Switched From 4:2 to 2:1 Schedule | 71 | Participants | ||
| Number of Participants With at Least 1 Filled Sunitinib Prescription | Axitinib | 53 | Participants | ||
| Number of Participants With 4:2 Sunitinib Schedule Without Any Modification | Sunitinib 4:2 Schedule | 704 | Participants | ||
| Number of Participants With 2:1 Sunitinib Schedule Without Any Modification | Sunitinib 2:1 Schedule | 320 | Participants | ||
| Number of Participants Switched From 4:2 Sunitinib Schedule to 2:1 Sunitinib Schedule | Sunitinib: Switched From 4:2 to 2:1 Schedule | 71 | Participants | ||
| Number of Participants on Second Line Treatment With at Least 1 Filled Axitinib Prescription | Axitinib | 110 | Participants | ||
| Time to Treatment Discontinuation (TTD) | Sunitinib 4:2 Schedule | 4.55 | 95% Confidence Interval 4.3 to 5.6 | Months | |
| Time to Treatment Discontinuation (TTD) | Sunitinib 2:1 Schedule | 6.20 | 95% Confidence Interval 5.6 to 7.2 | Months | |
| Time to Treatment Discontinuation (TTD) | Sunitinib: Switched From 4:2 to 2:1 Schedule | 13.91 | 95% Confidence Interval 8.1 to 20.6 | Months | |
| Time to Treatment Discontinuation (TTD) | Axitinib | 5.19 | 95% Confidence Interval 3.7 to 6.1 | Months | |
| Overall Survival (OS) | Sunitinib 4:2 Schedule | 13.48 | 95% Confidence Interval 12.3 to 15.8 | Months | |
| Overall Survival (OS) | Sunitinib 2:1 Schedule | 21.79 | 95% Confidence Interval 18.1 to 26.1 | Months | |
| Overall Survival (OS) | Sunitinib: Switched From 4:2 to 2:1 Schedule | 32.20 | 95% Confidence Interval 25.1 to 48.3 | Months | |
| Overall Survival (OS) | Axitinib | 12.23 | 95% Confidence Interval 7.7 to 14.2 | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04669366/results